Company profile
ZAI LAB LTD
NASDAQ:ZLABBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NIRAPARIB | phase3 | — | 6 | completed, terminated, unknown |
| ZOCILURTATUG PELITECAN | phase3 | — | 4 | active |
| RIPRETINIB | phase2 | — | 2 | no active trials |
| ADAGRASIB | phase1 | — | 18 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05859464 | phase1 | terminated | 2023-07-24 | 2025-08-28 | Zai Lab (Hong Kong), Ltd. | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors |
| NCT07658482 | phase1 | not_yet_recruiting | 2026-09-03 | 2027-02-06 | Zai Lab (Shanghai) Co., Ltd. | A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers |
| NCT07235384 | phase1 | recruiting | 2025-12-01 | 2027-12-28 | Zai Lab (Shanghai) Co., Ltd. | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis |
| NCT03516071 | phase2 | completed | 2017-05-17 | 2018-11-09 | Zai Lab (Shanghai) Co., Ltd. | A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC |
| NCT06380907 | phase2 | terminated | 2024-05-22 | 2025-12-16 | Zai Lab (Hong Kong), Ltd. | A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis |
FDA applications (0)
No records yet.